Abstract
Background: Protease activated receptor-1 (PAR1) is a G-coupled receptor activated by α-thrombin and other proteases. Several reports have demonstrated the PAR1 involvement in tumorigenesis and tumor progression. In order to investigate on potential use of PAR1 antagonists as antiproliferative agents.
Aims: We have identified a series of arylpiperazine derivatives acting as PAR1 antagonists; the selected molecules have been evaluated for their antiproliferative properties. Method: All the compounds inhibited the growth of a panel of cell lines expressing PAR1; two of them, compounds 13 and 15, were able to inhibit, in a dose dependent manner, the growth of the selected cell lines with the lowest IC50 values, and were further characterized to define the mechanism responsible for the observed antiproliferative effect. Result: This study directed us to the identification of two interesting leads that may help to further validate PAR1 as an important therapeutic target for cancer treatment.Keywords: Antagonists, antiproliferative agents, arylpiperazines, protease activated receptor-1.
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents
Volume: 17 Issue: 7
Author(s): Andrea Ilaria Zotti, Elena Di Gennaro, Angela Corvino, Francesco Frecentese, Elisa Magli, Elisa Perissutti, Giuseppe Cirino, Fiorentina Roviezzo, Manuela Terranova-Barberio, Federica Iannelli, Giuseppe Caliendo, Vincenzo Santagada, Ferdinando Fiorino, Alfredo Budillon and Beatrice Severino*
Affiliation:
- Department of Pharmacy, University of Naples ,Italy
Keywords: Antagonists, antiproliferative agents, arylpiperazines, protease activated receptor-1.
Abstract: Background: Protease activated receptor-1 (PAR1) is a G-coupled receptor activated by α-thrombin and other proteases. Several reports have demonstrated the PAR1 involvement in tumorigenesis and tumor progression. In order to investigate on potential use of PAR1 antagonists as antiproliferative agents.
Aims: We have identified a series of arylpiperazine derivatives acting as PAR1 antagonists; the selected molecules have been evaluated for their antiproliferative properties. Method: All the compounds inhibited the growth of a panel of cell lines expressing PAR1; two of them, compounds 13 and 15, were able to inhibit, in a dose dependent manner, the growth of the selected cell lines with the lowest IC50 values, and were further characterized to define the mechanism responsible for the observed antiproliferative effect. Result: This study directed us to the identification of two interesting leads that may help to further validate PAR1 as an important therapeutic target for cancer treatment.Export Options
About this article
Cite this article as:
Zotti Ilaria Andrea, Di Gennaro Elena, Corvino Angela, Frecentese Francesco, Magli Elisa, Perissutti Elisa, Cirino Giuseppe, Roviezzo Fiorentina, Terranova-Barberio Manuela, Iannelli Federica, Caliendo Giuseppe, Santagada Vincenzo, Fiorino Ferdinando, Budillon Alfredo and Severino Beatrice*, Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (7) . https://dx.doi.org/10.2174/1871520616666160926120904
DOI https://dx.doi.org/10.2174/1871520616666160926120904 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploring Patterns of Epigenetic Information with Data Mining Techniques
Current Pharmaceutical Design Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Aquaporin and Blood Brain Barrier
Current Neuropharmacology Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Subject Index to Volume 4
Current Pharmaceutical Biotechnology Synthesis of (R)-2-benzylmorpholine employing catalytic stereospecific rearrangement of L-Phenylalaninol
Letters in Organic Chemistry An Efficient Light-weight Network for Fast Reconstruction on MR Images
Current Medical Imaging Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Mesenchymal stem cell therapy for inflammatory bowel diseases: promise and challenge
Current Stem Cell Research & Therapy Expression and Function of Angiomodulating Cytokines in Rheumatoid Arthritis and Experimental Arthritis: Important Therapeutic Targets
Current Immunology Reviews (Discontinued) Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Imaging Methods in Gene Therapy of Cancer
Current Gene Therapy MMP14 Regulates VEGFR3 Expression on Corneal Epithelial Cells
Protein & Peptide Letters Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Transposons for Gene Therapy!
Current Gene Therapy Editorial
Current Radiopharmaceuticals Lysophospholipids: Synthesis and Biological Aspects
Current Organic Chemistry Separation of Ginseng Active Ingredients and their Roles in Cancer Metastasis Supplementary Therapy
Current Drug Metabolism Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery iNOS: A Potential Therapeutic Target for Malignant Glioma
Current Molecular Medicine